BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho JY, Sohn W, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park CG. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely. J Viral Hepat 2020;27:951-4. [PMID: 32338803 DOI: 10.1111/jvh.13306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng W, Liu M, Peng S, Yu G, Zhai X, Chen X, Lu F. Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients? J Viral Hepat 2020;27:1509-10. [PMID: 32741086 DOI: 10.1111/jvh.13369] [Reference Citation Analysis]
2 Lee H, Jang S, Ahn SH, Kim BK. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL. Hepatol Int 2022. [PMID: 35322374 DOI: 10.1007/s12072-022-10310-1] [Reference Citation Analysis]
3 Lu YX, He CZ, Wang YX, Ai ZS, Liang P, Yang CQ. Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study. Infect Dis Ther 2021;10:241-52. [PMID: 33111216 DOI: 10.1007/s40121-020-00355-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]